Anti-Tumor Effect against Human Cancer Xenografts by a Fully Human Monoclonal Antibody to a Variant 8-Epitope of CD44R1 Expressed on Cancer Stem Cells
Authors:
Open Access
- 17 January 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (1) , e29728
Abstract
CD44 is a major cellular receptor for hyaluronic acids. The stem structure of CD44 encoded by ten normal exons can be enlarged by ten variant exons (v1-v10) by alternative splicing. We have succeeded in preparing MV5 fully human IgM and its class-switched GV5 IgG monoclonal antibody (mAb) recognizing the extracellular domain of a CD44R1 isoform that contains the inserted region coded by variant (v8, v9 and v10) exons and is expressed on the surface of various human epithelial cancer cells. We demonstrated the growth inhibition of human cancer xenografts by a GV5 IgG mAb reshaped from an MV5 IgM. The epitope recognized by MV5 and GV5 was identified to a v8-coding region by the analysis of mAb binding to various recombinant CD44 proteins by enzyme-linked immunosorbent assay. GV5 showed preferential reactivity against various malignant human cells versus normal human cells assessed by flow cytometry and immunohistological analysis. When ME180 human uterine cervix carcinoma cells were subcutaneously inoculated to athymic mice with GV5, significant inhibition of tumor formation was observed. Furthermore, intraperitoneal injections of GV5markedly inhibited the growth of visible established tumors from HSC-3 human larynx carcinoma cells that had been subcutaneously transplanted one week before the first treatment with GV5. From in vitro experiments, antibody-dependent cellular cytotoxicity and internalization of CD44R1 seemed to be possible mechanisms for in vivo anti-tumor activity by GV5. CD44R1 is an excellent molecular target for mAb therapy of cancer, possibly superior to molecules targeted by existing therapeutic mAb, such as Trastuzumab and Cetuximab recognizing human epidermal growth factor receptor family.Keywords
This publication has 46 references indexed in Scilit:
- Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapyBiochemical and Biophysical Research Communications, 2011
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences, 2009
- Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoproteinCancer Science, 2009
- CD44s and CD44v6 Expression in Head and Neck EpitheliaPLOS ONE, 2008
- Phenotypic characterization of human colorectal cancer stem cellsProceedings of the National Academy of Sciences, 2007
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- Malignant Transformation of NIH3T3 Cells by Overexpression of Early Lymphocyte Activation Antigen CD98Biochemical and Biophysical Research Communications, 1999
- A family of ligands for the TNF receptor superfamilyStem Cells, 1994
- Expression and modulation of CD44 variant isoforms in humansJournal of Cell Biology, 1994
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990